Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The Consequences of Caronia: Impact On FDA’s Off-Label Regulation

Jan 29 2013

• By Kate Rawson

Related Content

GSK’s DoJ Settlement Links Executive Bonus To Continued Compliance

Jul 09 2012

FDA’s Very Big Year: Drug Approvals Approach Record Levels

Jan 16 2013

Off-Label Sales in Jeopardy: Rx Industry Fights for Clarity

Dec 01 2007

Off-Label Enforcement, Not Promotion, May See First Changes After Free Speech Ruling

Dec 10 2012

Off-Label Use Discussions Should Stay Off-line, FDA Draft Guidance Says

Jan 02 2012

FDA’s Social Media Guidance: As Industry Waits, How Watchful Should It Be?

Jun 27 2012

REMS Use Declining, But Post-Marketing Requirements Remain

Nov 01 2011

A Regulator’s Perspective For 2013: FDA’s Temple Discusses FDASIA, <em>Caronia</em>, and Breakthrough Development

Jan 22 2013

Related Companies

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc

GSK plc

Salix Pharmaceuticals Ltd.

Jaguar Health, Inc.

Additional Topics

United States Regulation Approvals Drug Approval Standards Compliance Advertising, Marketing & Sales Distribution Legal Issues BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window